PURPOSE: The
goal of this
registry was to collect
patient characteristics and
safety data from
patients from the
Asia -Pacific region with early
breast cancer receiving
adjuvant chemotherapy containing
docetaxel (
Taxotere (R)).
METHODS: This
registry was open-label, international, longitudinal, multicenter, and observational in design and included a prospective group of consecutive early
breast cancer patients with an intermediate-to-high
risk of
recurrence being treated with various
docetaxel -based (
anthracycline and non-
anthracycline )
adjuvant chemotherapy regimens during 2009-2013 in real-world clinical settings.
RESULTS: The
analysis included 1,712
patients , 79% of whom received
docetaxel -based,
anthracycline -containing regimens, while 21% received non-
anthracycline -containing regimens.
Patients receiving adjuvant
docetaxel -based
chemotherapy were followed for 1.5 years.
Chemotherapy -related adverse events (AEs) were reported by 76.2% of
patients (
anthracycline -containing vs. non-
anthracycline -containing regimens 76.8% vs. 74.1%). Serious AEs were reported in 12% of
patients (12.3% vs. 10%).
National Cancer Institute Common Terminology Criteria for Adverse Events grade 3 or higher
neutropenia was reported in 20% of
patients (21.6% vs. 13.9%),
leukopenia in 7.4% of
patients (5.4% vs. 14.8%), and
vomiting in 1.6% of
patients (1.8% vs. 0.6%).
Treatment -related
death was reported in 27
patients (1.6%), while only 3% of
patients had a
relapse .
Low-density lipoprotein cholesterol /
high-density lipoprotein cholesterol (HDL-C) and total
cholesterol /HDL-C ratios increased after
chemotherapy . A clinically insignificant reduction of 1.9% in left
ventricular ejection fraction , from 66.43 to 64.53, was observed 1.5 years after
therapy was completed.
CONCLUSION: The
Asia -Pacific
Breast initiative II
registry identified a variety of important facts regarding
patient population characteristics ,
disease epidemiology and
treatment response for early
breast cancer patients of the
Asia -Pacific region receiving
docetaxel -based
chemotherapy .
Docetaxel -based
chemotherapy did not show any significant
safety concerns for early
breast cancer patients of the
Asia -Pacific region, and thus may represent a safe
adjuvant chemotherapy regimen for these
patients .